Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.
Article Details
- CitationCopy to clipboard
Wingard JB, Mah FS
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.
Clin Ophthalmol. 2011;5:201-7. doi: 10.2147/OPTH.S8665. Epub 2011 Feb 15.
- PubMed ID
- 21386912 [ View in PubMed]
- Abstract
Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to other agents within the class of H(1)-antihistamines, but there are no clinical trial data to suggest that it holds any specific advantages over other agents.
DrugBank Data that Cites this Article
- Drugs